Key result
LMWH outperforms UFH for VTE in pregnancy due to lower bleeding, thrombocytopenia, and osteoporosis risks.
Why the study?
Diagnosis and treatment of venous thromboembolism in pregnant women are more difficult than in non-pregnant women, and pregnant patients were excluded from major clinical trials on acute thromboembolism therapies.
Does low molecular weight heparin improve safety and efficacy compared to unfractionated heparin in pregnant women with venous thromboembolism?
Population
Pregnant women with venous thromboembolism
Comparison
Low molecular weight heparin vs unfractionated heparin
Design
Review
Authors
Loading...
Supports LMWH preference in pregnancy VTE from review data; leaves open need for RCTs on efficacy endpoints.
Does low molecular weight heparin improve safety and efficacy compared to unfractionated heparin in pregnant women with venous thromboembolism?
Low molecular weight heparin is the recommended anticoagulant for venous thromboembolism in pregnancy due to its superior safety profile compared to unfractionated heparin.
Diaconu et al. (2013) conducted a review in Venous thromboembolism in pregnancy. Low molecular weight heparin vs. Unfractionated heparin was evaluated. Low molecular weight heparin is recommended over unfractionated heparin for venous thromboembolism in pregnancy due to lower risks of bleeding, thrombocytopenia, and osteoporosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: